[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 18 of about 18
1. Süveges I: [Intraocular tumours]. Magy Onkol; 2005;49(1):9-13
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Intraocular tumours may be benign or malignant.
  • Two of them deserve special attention: melanoma malignum oculi in adults and retinoblastoma in children.
  • Melanoma malignum may arise from all three areas of the uvea: the iris, the ciliary body and the choroid.
  • The more malignant growths are those which are situated closer to the posterior pole.
  • Histologically the epitheloid cell-type of melanoma is more malignant than those containing only spindle cells.
  • Their treatment depends on the size: in the case of large tumours enucleation is required, while for the smaller ones, radiation therapy can be applied.
  • Sixty-seven percent of the inherited-type cases are bilateral.
  • A white tissue mass growing into the vitreous is seen on the fundus.
  • Histologically the tumour contains malignant neuroepithelial cells, which may form a rosette.
  • In the case of large tumours the treatment is enucleation; in bilateral processes the bulbus with the larger mass is removed and the other eye is treated with radiation therapy.
  • In both cases chemotherapy is used according to a prescribed schedule.
  • These are treated with radiotherapy, chemotherapy and hormone therapy.
  • [MeSH-minor] Humans. Lymphoma / diagnosis. Lymphoma / therapy. Melanoma / diagnosis. Melanoma / therapy. Retinal Neoplasms / diagnosis. Retinal Neoplasms / therapy. Retinoblastoma / diagnosis. Retinoblastoma / therapy

  • MedlinePlus Health Information. consumer health - Eye Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15902327.001).
  • [ISSN] 0025-0244
  • [Journal-full-title] Magyar onkologia
  • [ISO-abbreviation] Magy Onkol
  • [Language] hun
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Hungary
  • [Number-of-references] 2
  •  go-up   go-down


2. Grabacka M, Placha W, Urbanska K, Laidler P, Płonka PM, Reiss K: PPAR gamma regulates MITF and beta-catenin expression and promotes a differentiated phenotype in mouse melanoma S91. Pigment Cell Melanoma Res; 2008 Jun;21(3):388-96
Hazardous Substances Data Bank. ALITRETINOIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] PPAR gamma regulates MITF and beta-catenin expression and promotes a differentiated phenotype in mouse melanoma S91.
  • Melanoma represents one of the most rapidly metastasizing, hence deadly tumors due to its high proliferation rate and invasiveness, characteristics of undifferentiated embryonic tissues.
  • Given the absence of effective therapy for metastatic melanoma, understanding more fully the molecular mechanisms underlying melanocyte differentiation may provide opportunities for novel therapeutic intervention.
  • Here we show that in mouse melanoma S91 cells activation of the peroxisome proliferator activated receptor (PPAR) gamma induces events resembling differentiation, such as growth arrest accompanied by apoptosis, spindle morphology and enhanced tyrosinase expression.
  • Beta-catenin, an MITF transcriptional activator, shows a similar pattern of decline during ciglitazone treatment, consistent with previous reports that activated PPAR gamma inhibits the Wnt/beta-catenin pathway through induction of beta-catenin proteasomal degradation.
  • The data suggest that PPAR gamma, besides its well-established role in mesenchymal cell differentiation towards adipocytes, might regulate differentiation in the melanocytic lineage.
  • [MeSH-major] Cell Differentiation. Gene Expression Regulation, Neoplastic. Melanoma / metabolism. Microphthalmia-Associated Transcription Factor / metabolism. PPAR gamma / physiology. beta Catenin / metabolism
  • [MeSH-minor] Animals. Antigens, Differentiation / biosynthesis. Antineoplastic Agents / pharmacology. Blotting, Western. Cell Cycle / drug effects. Cell Cycle / genetics. Cell Line, Tumor. Cell Shape / drug effects. Fluorescent Antibody Technique. Melanocytes / cytology. Mice. Monophenol Monooxygenase / metabolism. Phenotype. Promoter Regions, Genetic. Reverse Transcriptase Polymerase Chain Reaction. Thiazolidinediones / pharmacology. Tretinoin / pharmacology. Up-Regulation / drug effects

  • MedlinePlus Health Information. consumer health - Melanoma.
  • Hazardous Substances Data Bank. ALL-TRANS-RETINOIC ACID .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Melanoma Res. 2005 Aug;15(4):305-13 [16034310.001]
  • [Cites] Neoplasia. 2005 Jun;7(6):575-84 [16036108.001]
  • [Cites] Front Biosci. 2006;11:733-42 [16146765.001]
  • [Cites] Nat Genet. 2005 Oct;37(10):1047-54 [16142232.001]
  • [Cites] Cell. 2005 Dec 2;123(5):903-15 [16325583.001]
  • [Cites] Oncogene. 2006 Jan 12;25(2):248-59 [16132038.001]
  • [Cites] J Invest Dermatol. 2006 Jan;126(1):142-53 [16417230.001]
  • [Cites] Clin Cancer Res. 2006 May 15;12(10):3028-36 [16707598.001]
  • [Cites] Mol Cell Biol. 2006 Aug;26(15):5827-37 [16847334.001]
  • [Cites] Endocrinology. 2006 Sep;147(9):4463-75 [16777971.001]
  • [Cites] Neoplasia. 2006 Oct;8(10):851-61 [17032502.001]
  • [Cites] Mol Cell Biol. 2006 Dec;26(23):8914-27 [17000761.001]
  • [Cites] Genes Dev. 2006 Dec 15;20(24):3426-39 [17182868.001]
  • [Cites] Nat Rev Cancer. 2007 Apr;7(4):246-55 [17384580.001]
  • [Cites] Mutat Res. 2000 Mar 17;448(2):121-38 [10725467.001]
  • [Cites] J Biol Chem. 2000 May 12;275(19):14013-6 [10747853.001]
  • [Cites] Neoplasia. 1999 Aug;1(3):231-40 [10935478.001]
  • [Cites] Stem Cells. 2001;19(1):1-11 [11209086.001]
  • [Cites] FASEB J. 2001 Sep;15(11):1971-8 [11532977.001]
  • [Cites] Arch Pathol Lab Med. 2001 Oct;125(10):1295-306 [11570904.001]
  • [Cites] Clin Cancer Res. 2002 May;8(5):1288-94 [12006550.001]
  • [Cites] Cell. 2002 Jun 14;109(6):707-18 [12086670.001]
  • [Cites] Pigment Cell Res. 2002 Aug;15(4):242-50 [12100489.001]
  • [Cites] Invest Ophthalmol Vis Sci. 2002 Aug;43(8):2533-9 [12147581.001]
  • [Cites] Oncol Res. 2002;13(1):3-8 [12201672.001]
  • [Cites] J Cell Biol. 2002 Sep 16;158(6):1079-87 [12235125.001]
  • [Cites] Mol Cancer Ther. 2002 Mar;1(5):357-63 [12489852.001]
  • [Cites] Pigment Cell Res. 2003 Jun;16(3):261-5 [12753399.001]
  • [Cites] J Nutr. 2003 Jul;133(7 Suppl):2425S-2433S [12840219.001]
  • [Cites] Br J Cancer. 2003 Jul 21;89(2):252-7 [12865912.001]
  • [Cites] Melanoma Res. 2003 Oct;13(5):447-56 [14512786.001]
  • [Cites] Br J Dermatol. 2004 Feb;150(2):179-85 [14996086.001]
  • [Cites] Br J Dermatol. 2004 Mar;150(3):462-8 [15030328.001]
  • [Cites] Curr Cancer Drug Targets. 2004 May;4(3):285-98 [15134535.001]
  • [Cites] J Clin Invest. 2004 Jul;114(1):94-103 [15232616.001]
  • [Cites] Arch Dermatol Res. 2004 Jul;296(2):54-8 [15278363.001]
  • [Cites] Cancer Res. 2004 Aug 1;64(15):5270-82 [15289333.001]
  • [Cites] Mol Cancer Ther. 2004 Oct;3(10):1249-62 [15486192.001]
  • [Cites] J Biol Chem. 2004 Oct 22;279(43):45020-7 [15308623.001]
  • [Cites] Neuron. 1989 Jul;3(1):1-12 [2695146.001]
  • [Cites] Eur J Biochem. 1991 Jun 1;198(2):317-26 [1674912.001]
  • [Cites] Genes Dev. 1994 Nov 15;8(22):2770-80 [7958932.001]
  • [Cites] Mol Cell Biol. 1994 Dec;14(12):7996-8006 [7969139.001]
  • [Cites] J Clin Invest. 1995 Aug;96(2):741-50 [7635967.001]
  • [Cites] Mol Cell Biol. 1996 Jul;16(7):3350-60 [8668150.001]
  • [Cites] Science. 1997 Mar 21;275(5307):1790-2 [9065403.001]
  • [Cites] Genes Dev. 1997 Aug 1;11(15):1987-98 [9271121.001]
  • [Cites] Mol Cell Biol. 1998 Sep;18(9):5099-108 [9710594.001]
  • [Cites] Pigment Cell Res. 1998 Jun;11(3):134-42 [9730320.001]
  • [Cites] Curr Opin Lipidol. 1999 Apr;10(2):151-9 [10327283.001]
  • [Cites] Am J Pathol. 1999 Sep;155(3):739-52 [10487832.001]
  • [Cites] APMIS. 2004 Jul-Aug;112(7-8):508-25 [15563313.001]
  • [Cites] Annu Rev Genet. 2004;38:365-411 [15568981.001]
  • [Cites] Cancer Cell. 2004 Dec;6(6):565-76 [15607961.001]
  • [Cites] J Cell Biol. 2005 Jan 3;168(1):35-40 [15623583.001]
  • [Cites] Nature. 2005 Feb 17;433(7027):764-9 [15716956.001]
  • [Cites] Cell Signal. 2005 Jul;17(7):809-16 [15763423.001]
  • [Cites] Acta Pharmacol Sin. 2005 Jun;26(6):753-61 [15916743.001]
  • [Cites] Oncogene. 2005 May 26;24(23):3748-58 [15782124.001]
  • [Cites] Nature. 2005 Jul 7;436(7047):117-22 [16001072.001]
  • [Cites] Curr Pharm Des. 2005;11(19):2525-31 [16026305.001]
  • [Cites] Pigment Cell Res. 2005 Aug;18(4):265-77 [16029420.001]
  • (PMID = 18444964.001).
  • [ISSN] 1755-1471
  • [Journal-full-title] Pigment cell & melanoma research
  • [ISO-abbreviation] Pigment Cell Melanoma Res
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / R01 CA095518
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antigens, Differentiation; 0 / Antineoplastic Agents; 0 / Microphthalmia-Associated Transcription Factor; 0 / PPAR gamma; 0 / Thiazolidinediones; 0 / beta Catenin; 5300-03-8 / alitretinoin; 5688UTC01R / Tretinoin; 74772-77-3 / ciglitazone; EC 1.14.18.1 / Monophenol Monooxygenase
  • [Other-IDs] NLM/ NIHMS463714; NLM/ PMC3951148
  •  go-up   go-down


3. Aida K, Monia K, Ahlem S, Dominique HT, Becima F, Sylvie F, Ridha KM: Agminated Spitz nevi arising on a nevus spilus after chemotherapy. Pediatr Dermatol; 2010 Jul-Aug;27(4):411-3
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Agminated Spitz nevi arising on a nevus spilus after chemotherapy.
  • We report here a further case in a child that is original because it is induced by chemotherapy.
  • A 3-year-old boy presented 3 months after the onset of a chemotherapy for a vesico-prostatic rhabdomyosarcoma, multiple pigmented papulo-nodules located on the face, neck, chest wall, and the higher back.
  • Histological examination of three excised nodules led to the diagnosis of Spitz nevus.
  • Our patient may have a high risk for melanoma since he has many criteria predisposing to this risk.
  • Some of these criteria are related to NS but we should also take into account the chemotherapy induction and the high number of Spitz nevi.
  • [MeSH-major] Antineoplastic Agents / adverse effects. Nevus, Epithelioid and Spindle Cell / chemically induced. Prostatic Neoplasms / drug therapy. Rhabdomyosarcoma / drug therapy. Skin Neoplasms / chemically induced. Urinary Bladder Neoplasms / drug therapy


Advertisement
4. Durrani AJ, Moir GC, Diaz-Cano SJ, Cerio R: Malignant melanoma in an 8-year-old Caribbean girl: diagnostic criteria and utility of sentinel lymph node biopsy. Br J Dermatol; 2003 Mar;148(3):569-72
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Malignant melanoma in an 8-year-old Caribbean girl: diagnostic criteria and utility of sentinel lymph node biopsy.
  • The incidence of malignant melanoma (MM) is continuing to rise, although childhood MM remains rare.
  • We describe an 8-year-old Afro-Caribbean girl who developed a non pigmented lesion on the tip of her left thumb, which persisted despite treatment in primary care with cryotherapy.
  • She underwent amputation of the distal phalanx of her thumb, together with positive sentinel lymph node (SLN) biopsy and subsequent axillary lymph node clearance and adjuvant chemotherapy.
  • MMs are very rare in this age and skin-type group, therefore requiring strict diagnostic criteria.
  • [MeSH-major] Melanoma / pathology. Sentinel Lymph Node Biopsy / methods. Skin Neoplasms / pathology. Thumb
  • [MeSH-minor] Axilla. Child. Diagnosis, Differential. Female. Humans. Lymph Node Excision. Nevus, Epithelioid and Spindle Cell / pathology

  • MedlinePlus Health Information. consumer health - Melanoma.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12653752.001).
  • [ISSN] 0007-0963
  • [Journal-full-title] The British journal of dermatology
  • [ISO-abbreviation] Br. J. Dermatol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  •  go-up   go-down


5. Taylor JL, Quiñones Maymí DM, Sporn TA, McAdam HP, Wahidi MM: Multiple lung nodules in a woman with a history of melanoma. Respiration; 2003 Sep-Oct;70(5):544-8
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Multiple lung nodules in a woman with a history of melanoma.
  • A 61-year-old Caucasian female presented with a 6-week history of dry persistent cough.
  • She had been diagnosed with melanoma on the left thigh 6 months earlier.
  • It was a spindle cell variant, Clark's grade III, with maximal thickness of 0.5 mm.
  • At the time of diagnosis of melanoma, there was no evidence of metastasis on chest radiographs or computed tomography (CT) of the abdomen and pelvis.
  • Treatment of her melanoma was limited to surgical excision with no subsequent radiation or chemotherapy.
  • [MeSH-major] Histiocytosis, Langerhans-Cell / diagnosis. Histiocytosis, Langerhans-Cell / epidemiology. Melanoma / epidemiology
  • [MeSH-minor] Comorbidity. Female. Humans. Middle Aged. Tomography, X-Ray Computed

  • MedlinePlus Health Information. consumer health - Melanoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2003 S. Karger AG, Basel
  • (PMID = 14665785.001).
  • [ISSN] 0025-7931
  • [Journal-full-title] Respiration; international review of thoracic diseases
  • [ISO-abbreviation] Respiration
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Switzerland
  •  go-up   go-down


6. Kravtsov VG, Zaĭrat'iants OV: [Clinical and morphological characteristics of gastrointestinal stromal tumors]. Arkh Patol; 2007 Sep-Oct;69(5):54-61
Genetic Alliance. consumer health - Gastrointestinal Stromal Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • GIST are stromal tumors and the gastrointestinal tract (GIT) and some other organs of spindle-cell or epithelioid-cell structure expressing CD117 (C-kit, KIT), as well as those at different rates and in different combinations, CD34, smooth muscle and/or neurogenic differentiation antigens.
  • This is supported by successful chemotherapy for GIST with a KIT receptor inhibitor.
  • The histogenesis of GIST is associated with GIT somatic stem, the Cajal cell precursors.
  • [MeSH-minor] Antigens, CD34 / biosynthesis. Antigens, CD34 / genetics. Apoptosis / genetics. Enzyme Activation / genetics. Epithelioid Cells / metabolism. Epithelioid Cells / pathology. Gene Expression Regulation, Neoplastic / genetics. Humans. Liver Neoplasms / drug therapy. Liver Neoplasms / genetics. Liver Neoplasms / metabolism. Liver Neoplasms / pathology. Liver Neoplasms / secondary. Melanoma / genetics. Melanoma / metabolism. Melanoma / pathology. Mitosis / genetics. Mutation. Myocytes, Smooth Muscle / metabolism. Myocytes, Smooth Muscle / pathology. Neoplasm Metastasis. Neoplastic Stem Cells / metabolism. Neoplastic Stem Cells / pathology. Peritoneal Neoplasms / drug therapy. Peritoneal Neoplasms / genetics. Peritoneal Neoplasms / pathology. Peritoneal Neoplasms / secondary. Sarcoma / drug therapy. Sarcoma / genetics. Sarcoma / metabolism. Sarcoma / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18074824.001).
  • [ISSN] 0004-1955
  • [Journal-full-title] Arkhiv patologii
  • [ISO-abbreviation] Arkh. Patol.
  • [Language] rus
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Russia (Federation)
  • [Chemical-registry-number] 0 / Antigens, CD34; EC 2.7.10.1 / Proto-Oncogene Proteins c-kit
  • [Number-of-references] 44
  •  go-up   go-down


7. Schoenfield L, Pettay J, Tubbs RR, Singh AD: Variation of monosomy 3 status within uveal melanoma. Arch Pathol Lab Med; 2009 Aug;133(8):1219-22
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Variation of monosomy 3 status within uveal melanoma.
  • CONTEXT: Determining the most significant prognostic variables in uveal melanoma is important for stratifying patients for metastasis surveillance and possible initiation of chemotherapy or immunotherapy.
  • DESIGN: Eighteen consecutive patients with uveal melanoma who underwent primary enucleation were studied.
  • The chromosomal analysis was also correlated with histologic evaluation for melanoma cell type (spindle vs epithelioid cell), ciliary body involvement, presence of positive periodic acid-Schiff vascular mimicry patterns, scleral or extrascleral spread and size.
  • Lack of concordance between the base and apex did not correlate with melanoma cell type.
  • CONCLUSIONS: Prognostic variables are important in management of neoplasms, and this study points out that the site of tissue biopsy for prognostication in uveal melanoma could affect the results obtained, at least for the presence of monosomy 3.
  • [MeSH-major] Chromosomes, Human, Pair 3 / genetics. Melanoma / genetics. Monosomy. Uveal Neoplasms / genetics
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Biopsy, Fine-Needle. DNA, Neoplasm / analysis. Eye Enucleation. Female. Follow-Up Studies. Humans. In Situ Hybridization, Fluorescence. Male. Middle Aged. Prognosis. Survival Rate

  • Genetic Alliance. consumer health - Uveal melanoma.
  • MedlinePlus Health Information. consumer health - Melanoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19653713.001).
  • [ISSN] 1543-2165
  • [Journal-full-title] Archives of pathology & laboratory medicine
  • [ISO-abbreviation] Arch. Pathol. Lab. Med.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / DNA, Neoplasm
  •  go-up   go-down


8. Ulamec M, Soldo-Belić A, Vucić M, Buljan M, Kruslin B, Tomas D: Melanoma with second myxoid stromal changes after personally applied prolonged phototherapy. Am J Dermatopathol; 2008 Apr;30(2):185-7
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Melanoma with second myxoid stromal changes after personally applied prolonged phototherapy.
  • Most malignant melanomas are easily diagnosed; however, melanoma is also one of the lesions most frequently reported to mimic other tumors.
  • A case is presented of primary cutaneous melanoma with abundant myxoid matrix in a patient who underwent prolonged phototherapy.
  • Clinically, the lesion was unevenly pigmented, ulcerated, covered with hemorrhagic crust, and measuring 3.5 cm in greatest dimension, with a satellite nodule.
  • Histologically, the primary tumor and metastases were composed of nests and pseudotubular formations of polygonal, spindle, and stellate cells embedded in abundant myxoid stroma that comprised more than 80% of the tumor mass.
  • Chemotherapy and immunotherapy were administered as suggested by an oncologist.
  • The patient died from distant metastases 6 months after the diagnosis.
  • Although some authors believe that myxoid changes do not seem to alter the behavior of melanoma, it remains an important differential diagnosis issue.
  • [MeSH-major] Cell Transformation, Neoplastic / pathology. Lymph Nodes / pathology. Melanoma / secondary. Phototherapy / methods. Skin Neoplasms / pathology
  • [MeSH-minor] Adult. Biopsy, Needle. Follow-Up Studies. Humans. Immunohistochemistry. Lymphatic Metastasis. Male. Neoplasm Staging. Risk Assessment. Time Factors

  • MedlinePlus Health Information. consumer health - Melanoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18360128.001).
  • [ISSN] 1533-0311
  • [Journal-full-title] The American Journal of dermatopathology
  • [ISO-abbreviation] Am J Dermatopathol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


9. Miyatani H, Yoshida Y, Ushimaru S, Sagihara N, Yamada S: Slow growing flat-type primary malignant melanoma of the esophagus treated with cap-assisted EMR. Dig Endosc; 2009 Oct;21(4):255-7
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Slow growing flat-type primary malignant melanoma of the esophagus treated with cap-assisted EMR.
  • We report a rare case of flat-type primary malignant melanoma of the esophagus treated with endoscopic mucosal resection (EMR).
  • The histopathological findings showed atypical melanocyte proliferation in the basal layer, spindle cells, and epithelioid cell proliferation with nuclear enlargement and a few mitotic figures.
  • Histopathological examination confirmed the diagnosis of primary malignant melanoma.
  • The patient was discharged without additional surgical resection and/or chemotherapy.
  • There has been no report on a slow growing esophageal melanoma.
  • It is difficult to estimate the malignant behavior of this case.
  • [MeSH-major] Endoscopy. Esophageal Neoplasms / pathology. Esophageal Neoplasms / surgery. Melanoma / pathology. Melanoma / surgery

  • MedlinePlus Health Information. consumer health - Endoscopy.
  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • MedlinePlus Health Information. consumer health - Melanoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19961525.001).
  • [ISSN] 1443-1661
  • [Journal-full-title] Digestive endoscopy : official journal of the Japan Gastroenterological Endoscopy Society
  • [ISO-abbreviation] Dig Endosc
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Australia
  •  go-up   go-down


10. Murakami M, Wada T, Kashiwagi T, Ishida-Yamamoto A, Iizuka H: Nodular malignant melanoma with Spitz nevus-like pathological features finally confirmed by the pathological feature of the sentinel lymph node. J Dermatol; 2007 Dec;34(12):821-8
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Nodular malignant melanoma with Spitz nevus-like pathological features finally confirmed by the pathological feature of the sentinel lymph node.
  • The clinical and histopathological similarities of nodular melanoma and Spitz nevus currently still make a definitive diagnosis difficult.
  • We report here a case of nodular melanoma that was extremely difficult to diagnose both clinically and histopathologically.
  • The primary tumor was a blackish nodule on the scalp and biopsy was performed for pathological diagnosis.
  • Although our first impression was malignant melanoma, we asked two dermatopathologists for second opinions; however, one diagnosed a melanoma and the other a Spitz nevus.
  • Histopathological diagnosis to establish whether it was a melanoma metastasis or nodal nevi was also difficult, and we again asked for second opinions from another dermatopathologist in the USA.
  • According to its clinical course and the histopathology of the sentinel lymph node with additional immunohistochemistry, this case was finally diagnosed as a nodular melanoma (T4aN1aM0, stage IIIA).
  • To date, the patient has been given five courses of chemotherapy at 6-month intervals, with no local recurrence or distant metastases so far.
  • [MeSH-major] Head and Neck Neoplasms / pathology. Melanoma / pathology. Scalp. Skin Neoplasms / pathology
  • [MeSH-minor] Adult. Humans. Male. Nevus, Epithelioid and Spindle Cell / pathology. Sentinel Lymph Node Biopsy


11. Silva EG, Deavers MT, Bodurka DC, Malpica A: Uterine epithelioid leiomyosarcomas with clear cells: reactivity with HMB-45 and the concept of PEComa. Am J Surg Pathol; 2004 Feb;28(2):244-9
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In this study, we investigated HMB-45 expression in epithelioid uterine leiomyosarcomas with clear cell areas.
  • 1) clear cell areas and 2) spindle cell areas that were at least focally positive for desmin and caldesmon.
  • Two received radiotherapy, and three were also treated with chemotherapy.
  • Four cases were positive for HMB-45 only in the clear cell areas.
  • In uterine smooth muscle tumors, some epithelioid cells most likely undergo clear cell changes and become positive for HMB-45.
  • [MeSH-major] Leiomyosarcoma / metabolism. Leiomyosarcoma / pathology. Neoplasm Proteins / metabolism. Uterine Neoplasms / metabolism. Uterine Neoplasms / pathology
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Antigens, Neoplasm. Epithelial Cells / pathology. Female. Humans. Immunohistochemistry / methods. Melanoma-Specific Antigens. Middle Aged. Staining and Labeling

  • MedlinePlus Health Information. consumer health - Uterine Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15043315.001).
  • [ISSN] 0147-5185
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, Neoplasm; 0 / Melanoma-Specific Antigens; 0 / Neoplasm Proteins
  •  go-up   go-down


12. Silva EG, Bodurka DC, Scouros MA, Ayala A: A uterine leiomyosarcoma that became positive for HMB45 in the metastasis. Ann Diagn Pathol; 2005 Feb;9(1):43-5
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Uterine smooth muscle tumors are usually spindle cell lesions, but a minority is composed of epithelioid cells.
  • Recently, it has been shown that some of these tumors can be positive for HMB45, and some authors have advocated calling these lesions perivascular epithelioid cell (PEC) tumors or PEComas.
  • The case we describe here clearly shows that the so called PEC is just a smooth muscle cell capable of changing its immunophenotype.
  • She was treated with a simple hysterectomy and bilateral salpingo-oophorectomy.
  • She, therefore, also received chemotherapy and was free of disease until October 2002, when a recurrent tumor was detected in her spine.
  • After undergoing resection of the lesion at 2 different times, in 2002 and 2003, the patient was treated with radiotherapy and is currently receiving chemotherapy.
  • However, although the tumors resected from the spine in 2002 and 2003 showed features similar to those of the uterine neoplasm, but with a lower percentage of cells positive for smooth muscle actin and more clear cells, several of the clear cells were positive for HMB45.
  • To the best of our knowledge, this is the first case of a uterine smooth muscle cell tumor that became positive for HMB45 when it metastasized.
  • [MeSH-major] Leiomyosarcoma / secondary. Liver Neoplasms / secondary. Neoplasm Proteins. Uterine Neoplasms / pathology
  • [MeSH-minor] Actins / analysis. Adult. Antigens, Neoplasm. Biomarkers, Tumor / analysis. Cell Count. Combined Modality Therapy. Epithelioid Cells / chemistry. Epithelioid Cells / pathology. Female. Humans. Melanoma-Specific Antigens. Neoplasm Metastasis / pathology. Neoplasm Metastasis / therapy

  • Genetic Alliance. consumer health - Leiomyosarcoma.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • MedlinePlus Health Information. consumer health - Uterine Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15692950.001).
  • [ISSN] 1092-9134
  • [Journal-full-title] Annals of diagnostic pathology
  • [ISO-abbreviation] Ann Diagn Pathol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Actins; 0 / Antigens, Neoplasm; 0 / Biomarkers, Tumor; 0 / Melanoma-Specific Antigens; 0 / Neoplasm Proteins
  •  go-up   go-down


13. Rutkowski P, Nowecki ZI, Debiec-Rychter M, Grzesiakowska U, Michej W, Woźniak A, Siedlecki JA, Limon J, vel Dobosz AJ, Kakol M, Osuch C, Ruka W: Predictive factors for long-term effects of imatinib therapy in patients with inoperable/metastatic CD117(+) gastrointestinal stromal tumors (GISTs). J Cancer Res Clin Oncol; 2007 Sep;133(9):589-97
Hazardous Substances Data Bank. IMATINIB MESYLATE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Predictive factors for long-term effects of imatinib therapy in patients with inoperable/metastatic CD117(+) gastrointestinal stromal tumors (GISTs).
  • THE PURPOSE: To analyze the outcomes of treatment and factors predicting effects of imatinib (IM) therapy in inoperable/metastatic gastrointestinal stromal tumors (GIST) CD117(+) patients.
  • Median follow-up time was 26 months.
  • The following factors significantly and negatively influenced PFS in univariate analysis: poor baseline World Health Organization (WHO) performance status > or = 2 (P < 0.00001), tumor genotype indicating other than KIT exon 11 isoform (P = 0.005), baseline high neutrophils count (P < 0.00001), age <45 years at the diagnosis (P = 0.04), mitotic index >10/50 high-power fields (HPF) (P = 0.001), GIST histological type other than spindle-cell (P = 0.03), baseline low albumin level (P = 0.0005), low baseline hemoglobin level (P < 0.00001), and primary overtly malignant tumors (unresectable and/or metastatic lesions at presentation) (P = 0.05).
  • CONCLUSIONS: We confirmed that many advanced GIST patients benefit from IM therapy for a prolonged time, although resistance to therapy is observed.
  • We identified four independent biological factors influencing the PFS during long-term IM therapy.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Gastrointestinal Stromal Tumors / drug therapy. Gastrointestinal Stromal Tumors / mortality. Piperazines / therapeutic use. Proto-Oncogene Proteins c-kit / metabolism. Pyrimidines / therapeutic use
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Benzamides. Child. DNA Mutational Analysis. Disease-Free Survival. Female. Humans. Imatinib Mesylate. Kaplan-Meier Estimate. Male. Middle Aged. Mutation. Prognosis. Receptor, Platelet-Derived Growth Factor alpha / genetics. Stem Cell Factor / genetics. Survival Analysis. Time Factors. Treatment Outcome

  • Genetic Alliance. consumer health - Gastrointestinal Stromal Tumors.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Virchows Arch. 2001 Jan;438(1):1-12 [11213830.001]
  • [Cites] Br J Cancer. 2004 Jun 1;90(11):2059-61 [15150562.001]
  • [Cites] Ann Surg. 2000 Jan;231(1):51-8 [10636102.001]
  • [Cites] Int J Cancer. 2002 Aug 1;100(4):463-71 [12115531.001]
  • [Cites] J Clin Oncol. 2006 Oct 10;24(29):4764-74 [16954519.001]
  • [Cites] J Natl Cancer Inst. 2000 Feb 2;92 (3):205-16 [10655437.001]
  • [Cites] Gastroenterology. 2005 Feb;128(2):270-9 [15685537.001]
  • [Cites] Ann Oncol. 2001 Oct;12(10):1423-32 [11762815.001]
  • [Cites] Hum Pathol. 2002 May;33(5):466-77 [12094371.001]
  • [Cites] J Clin Oncol. 2004 Sep 15;22(18):3813-25 [15365079.001]
  • [Cites] J Clin Oncol. 2005 Aug 20;23(24):5795-804 [16110036.001]
  • [Cites] N Engl J Med. 2002 Aug 15;347(7):472-80 [12181401.001]
  • [Cites] Ann Surg Oncol. 2007 Jan;14(1):134-42 [17080234.001]
  • [Cites] Hum Pathol. 2002 May;33(5):459-65 [12094370.001]
  • [Cites] Lancet. 2004 Sep 25-Oct 1;364(9440):1127-34 [15451219.001]
  • [Cites] Curr Opin Oncol. 2006 Jul;18(4):386-95 [16721136.001]
  • [Cites] Cancer Chemother Pharmacol. 2005 Apr;55(4):379-86 [15592836.001]
  • [Cites] J Clin Oncol. 2003 Dec 1;21(23):4342-9 [14645423.001]
  • [Cites] Science. 1998 Jan 23;279(5350):577-80 [9438854.001]
  • [Cites] Eur J Cancer. 2006 May;42(8):1093-103 [16624552.001]
  • [Cites] Clin Cancer Res. 2006 Mar 15;12(6):1743-9 [16551858.001]
  • [Cites] Semin Diagn Pathol. 2006 May;23(2):91-102 [17193822.001]
  • [Cites] Ann Oncol. 2005 Apr;16(4):566-78 [15781488.001]
  • [Cites] Eur J Cancer. 2004 Mar;40(5):689-95 [15010069.001]
  • [Cites] Lancet. 2001 Oct 27;358(9291):1421-3 [11705489.001]
  • [Cites] AJR Am J Roentgenol. 2004 Dec;183(6):1619-28 [15547201.001]
  • [Cites] Eur J Cancer. 2002 Sep;38 Suppl 5:S83-7 [12528778.001]
  • (PMID = 17458563.001).
  • [ISSN] 0171-5216
  • [Journal-full-title] Journal of cancer research and clinical oncology
  • [ISO-abbreviation] J. Cancer Res. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Benzamides; 0 / Piperazines; 0 / Pyrimidines; 0 / Stem Cell Factor; 8A1O1M485B / Imatinib Mesylate; EC 2.7.10.1 / Proto-Oncogene Proteins c-kit; EC 2.7.10.1 / Receptor, Platelet-Derived Growth Factor alpha
  •  go-up   go-down


14. Farina HG, Pomies M, Alonso DF, Gomez DE: Antitumor and antiangiogenic activity of soy isoflavone genistein in mouse models of melanoma and breast cancer. Oncol Rep; 2006 Oct;16(4):885-91
Hazardous Substances Data Bank. GENISTEIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Antitumor and antiangiogenic activity of soy isoflavone genistein in mouse models of melanoma and breast cancer.
  • Tumor invasion, angiogenesis and metastasis involve secretion of proteolytic enzymes and cell migration into blood vessels.
  • Tumor cells are capable of degrading the extracellular matrix via a proteolytic cascade that includes urokinase-type plasminogen activator (uPA) and matrix metalloproteases (MMPs).
  • We have investigated the antitumor and antiangiogenic properties of soy isoflavone genistein in B16 melanoma and F3II mammary carcinoma mouse models.
  • At non-cytotoxic concentrations (0.1-50 microM) genistein induced dose-dependent spindle-cell morphology and significantly reduced motility in both cell lines.
  • Genistein inhibited uPA secreted by F3II cell monolayers, while inducing an increase in the proteolytic activity of B16 cells.
  • Similar antiangiogenic effects were obtained with a soybean-based diet.
  • This data suggest that tumor cell migration and proteolysis may be associated with the antitumor and antiangiogenic activity of soy isoflavone genistein.
  • [MeSH-major] Antineoplastic Agents / pharmacology. Genistein / pharmacology. Isoflavones / therapeutic use. Mammary Neoplasms, Animal / drug therapy. Melanoma / drug therapy. Soybeans / chemistry
  • [MeSH-minor] Angiogenesis Inhibitors / pharmacology. Animals. Culture Media, Conditioned / metabolism. Disease Models, Animal. Humans. Melanoma, Experimental. Mice. Mice, Inbred C57BL. Neovascularization, Pathologic

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Melanoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16969510.001).
  • [ISSN] 1021-335X
  • [Journal-full-title] Oncology reports
  • [ISO-abbreviation] Oncol. Rep.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Angiogenesis Inhibitors; 0 / Antineoplastic Agents; 0 / Culture Media, Conditioned; 0 / Isoflavones; DH2M523P0H / Genistein
  •  go-up   go-down


15. Wu Q, Liu C, Lei L, Yan X, Wang B, Liu X, Yv L, Lv Y: Interdigitating dendritic cell sarcoma involving bone marrow in a liver transplant recipient. Transplant Proc; 2010 Jun;42(5):1963-6
MedlinePlus Health Information. consumer health - Liver Transplantation.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Interdigitating dendritic cell sarcoma involving bone marrow in a liver transplant recipient.
  • Liver transplantation is an effective treatment for patients with many kinds of liver diseases.
  • However, an increased risk of de novo malignancy has been reported in liver transplant recipients; immunosuppressive drugs have generally been identified as the primary culprit.
  • Interdigitating dendritic cell sarcoma (IDCS) is an exceedingly rare neoplasm arising from antigen-presenting cells of the immune system.
  • In this study, we have reported a case of IDCS with bone marrow involvement occurring in a 61-year-old female liver transplant recipient at 2 years after the procedure.
  • Routine examination revealed an abnormal white blood cell count and elevated serum lactate dehydrogenase.
  • Computerized tomography of the chest, abdomen, and pelvis were negative.
  • To obtain a definite diagnosis, we performed an excisional lymph node biopsy and a bone marrow biopsy.
  • Microscopically, the tumor was composed of spindle cells with pale to eosinophilic cytoplasm, ill-defined cell borders, and large pleomorphic nuclei with prominent nucleoli.
  • Follicular dendritic cell, lymphoid, epithelial, myoepithelial, and melanoma markers were negative.
  • She responded to chemotherapy.
  • This case demonstrates the importance of cancer prevention and early detection for liver transplant recipients.
  • [MeSH-major] Bone Marrow / pathology. Carcinoma, Hepatocellular / surgery. Dendritic Cell Sarcoma, Interdigitating / complications. Liver Neoplasms / surgery. Liver Transplantation / methods
  • [MeSH-minor] Female. Hepatitis B / complications. Humans. Liver Cirrhosis / surgery. Liver Cirrhosis / virology. Lymph Nodes / pathology. Middle Aged. Treatment Outcome

  • Genetic Alliance. consumer health - Liver Transplant.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20620556.001).
  • [ISSN] 1873-2623
  • [Journal-full-title] Transplantation proceedings
  • [ISO-abbreviation] Transplant. Proc.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


16. Hewes CA, Sullins KE: Use of cisplatin-containing biodegradable beads for treatment of cutaneous neoplasia in equidae: 59 cases (2000-2004). J Am Vet Med Assoc; 2006 Nov 15;229(10):1617-22
Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Use of cisplatin-containing biodegradable beads for treatment of cutaneous neoplasia in equidae: 59 cases (2000-2004).
  • RESULTS: 22 tumors were sarcoids, 6 were fibrosarcomas, 1 was a fibroma, 2 were peripheral nerve sheath tumors, 11 were squamous cell carcinomas, 14 were melanomas (13 gray horses and 1 bay horse), 1 was a lymphosarcoma, 1 was an adenocarcinoma, and 1 was a basal cell tumor.
  • Forty of 48 (83%) animals for which long-term follow-up information was available were relapse free 2 years after treatment.
  • This included 20 of 22 animals with spindle cell tumors (including 11/13 horses with sarcoids), 6 of 10 animals with squamous cell carcinomas, 13 of 14 animals with melanomas, and 2 of 3 animals with other tumor types.
  • CONCLUSIONS AND CLINICAL RELEVANCE: Results suggest that implantation of cisplatin-containing biodegradable beads, with or without tumor debulking, may be an effective treatment for equidae with various cutaneous neoplasms.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Cisplatin / therapeutic use. Equidae. Horse Diseases / drug therapy. Skin Neoplasms / veterinary
  • [MeSH-minor] Animals. Carcinoma, Squamous Cell / drug therapy. Carcinoma, Squamous Cell / surgery. Carcinoma, Squamous Cell / veterinary. Female. Horses. Laser Therapy / methods. Laser Therapy / veterinary. Male. Melanoma / drug therapy. Melanoma / surgery. Melanoma / veterinary. Retrospective Studies. Sarcoma / drug therapy. Sarcoma / surgery. Sarcoma / veterinary. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17107319.001).
  • [ISSN] 0003-1488
  • [Journal-full-title] Journal of the American Veterinary Medical Association
  • [ISO-abbreviation] J. Am. Vet. Med. Assoc.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


17. Mahboobi S, Pongratz H, Hufsky H, Hockemeyer J, Frieser M, Lyssenko A, Paper DH, Bürgermeister J, Böhmer FD, Fiebig HH, Burger AM, Baasner S, Beckers T: Synthetic 2-aroylindole derivatives as a new class of potent tubulin-inhibitory, antimitotic agents. J Med Chem; 2001 Dec 20;44(26):4535-53
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • A new class of simple synthetic antimitotic compounds based on 2-aroylindoles was discovered. (5-Methoxy-1H-2-indolyl)-phenylmethanone (1) as well as analogous 3-fluorophenyl- (36) and 3-methoxyphenyl (3) derivatives displayed high cytotoxicity of IC(50) = 20 to 75 nM against the human HeLa/KB cervical, SK-OV-3 ovarian, and U373 astrocytoma carcinoma cell lines.
  • The inhibition of proliferation correlated with the arrest in the G2/M phase of the cell cycle.
  • Thus, the antimitotic activity of 2-aroylindoles is explained by interference with the mitotic spindle apparatus and destabilization of microtubules.
  • In xenograft experiments, 1 was highly active after oral administration at 200 mg/kg against the human amelanocytic melanoma MEXF 989 in athymic nude mice.
  • We conclude, that 2-aroylindoles constitute an interesting new class of antitubulin agents with the potential to be clinically developed for cancer treatment.
  • [MeSH-minor] Allantois / blood supply. Angiogenesis Inhibitors / chemical synthesis. Angiogenesis Inhibitors / chemistry. Angiogenesis Inhibitors / pharmacology. Animals. Biopolymers. Cattle. Chorion / blood supply. Drug Screening Assays, Antitumor. G2 Phase / drug effects. GTP Phosphohydrolases / chemistry. Humans. In Vitro Techniques. Melanoma / drug therapy. Mice. Mice, Nude. Mitosis / drug effects. Structure-Activity Relationship. Transplantation, Heterologous. Tumor Cells, Cultured

  • COS Scholar Universe. author profiles.
  • BindingDB. BindingDB .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11741473.001).
  • [ISSN] 0022-2623
  • [Journal-full-title] Journal of medicinal chemistry
  • [ISO-abbreviation] J. Med. Chem.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Angiogenesis Inhibitors; 0 / Antineoplastic Agents; 0 / Biopolymers; 0 / Indoles; 0 / Tubulin; EC 3.6.1.- / GTP Phosphohydrolases
  •  go-up   go-down


18. Prayson RA, Sebek BA: Parotid gland malignant melanomas. Arch Pathol Lab Med; 2000 Dec;124(12):1780-4
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Parotid gland malignant melanomas.
  • BACKGROUND: Malignant melanomas are relatively unusual tumors in the parotid gland.
  • METHODS: Retrospective clinicopathologic review of 12 cases of malignant melanoma involving the parotid gland encountered between 1980 and October 1999 at a tertiary referral center.
  • Eleven of 12 patients presented with a neck mass or nodule.
  • In 2 patients, a cutaneous melanoma and the parotid gland melanoma were diagnosed at the same time.
  • In 1 patient, melanoma was initially diagnosed in the parotid gland, and a definite primary was not uncovered.
  • All patients underwent excision of the parotid melanoma, which was accompanied by a lymph node biopsy or dissection in 10 out of 11 patients.
  • Four patients received adjuvant radiotherapy, and 3 patients received adjuvant chemotherapy.
  • Four of 11 patients had ipsilateral cervical lymph node metastasis at the time of parotid tumor resection, and 5 patients had involvement of intraparotid lymph nodes by metastatic melanoma.
  • Four tumors demonstrated focal spindle cell regions.
  • Prognosis is generally poor, although rare patients may survive a long period of time following surgery.
  • [MeSH-major] Melanoma / pathology. Parotid Neoplasms / secondary. Skin Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Melanoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11100057.001).
  • [ISSN] 0003-9985
  • [Journal-full-title] Archives of pathology & laboratory medicine
  • [ISO-abbreviation] Arch. Pathol. Lab. Med.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] UNITED STATES
  •  go-up   go-down






Advertisement